Proficio Capital Partners LLC Takes $405,000 Position in Elanco Animal Health Incorporated (NYSE:ELAN)

Proficio Capital Partners LLC acquired a new stake in Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 33,460 shares of the company's stock, valued at approximately $405,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Wilmington Savings Fund Society FSB bought a new stake in shares of Elanco Animal Health in the 3rd quarter valued at $35,000. Jones Financial Companies Lllp increased its holdings in Elanco Animal Health by 95.6% in the fourth quarter. Jones Financial Companies Lllp now owns 4,212 shares of the company's stock worth $51,000 after purchasing an additional 2,059 shares in the last quarter. SRS Capital Advisors Inc. lifted its stake in Elanco Animal Health by 221.2% in the fourth quarter. SRS Capital Advisors Inc. now owns 4,953 shares of the company's stock valued at $60,000 after buying an additional 3,411 shares during the period. Blue Trust Inc. boosted its holdings in shares of Elanco Animal Health by 47.7% during the 4th quarter. Blue Trust Inc. now owns 5,862 shares of the company's stock worth $71,000 after buying an additional 1,894 shares in the last quarter. Finally, Spire Wealth Management increased its stake in shares of Elanco Animal Health by 107.4% in the 4th quarter. Spire Wealth Management now owns 7,776 shares of the company's stock valued at $94,000 after acquiring an additional 4,026 shares in the last quarter. Institutional investors own 97.48% of the company's stock.

Elanco Animal Health Price Performance

ELAN traded down $0.42 on Friday, reaching $10.40. The company had a trading volume of 4,189,495 shares, compared to its average volume of 4,778,495. Elanco Animal Health Incorporated has a 52-week low of $10.03 and a 52-week high of $18.80. The company has a market cap of $5.14 billion, a price-to-earnings ratio of 25.99, a P/E/G ratio of 2.50 and a beta of 1.44. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.31 and a current ratio of 2.55. The business has a 50 day simple moving average of $11.27 and a 200 day simple moving average of $12.48.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last released its quarterly earnings data on Tuesday, February 25th. The company reported $0.14 earnings per share for the quarter, missing analysts' consensus estimates of $0.15 by ($0.01). Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. The company had revenue of $1.02 billion for the quarter, compared to analysts' expectations of $1.01 billion. During the same period last year, the company posted $0.08 EPS. The business's revenue for the quarter was down 1.4% compared to the same quarter last year. As a group, sell-side analysts anticipate that Elanco Animal Health Incorporated will post 0.91 EPS for the current year.

Analyst Ratings Changes

Several research analysts have issued reports on ELAN shares. Leerink Partnrs upgraded Elanco Animal Health to a "hold" rating in a report on Monday, December 2nd. Piper Sandler reduced their target price on shares of Elanco Animal Health from $16.00 to $12.00 and set a "neutral" rating for the company in a research report on Thursday, March 6th. Barclays lowered their price target on shares of Elanco Animal Health from $20.00 to $19.00 and set an "overweight" rating on the stock in a report on Wednesday, February 26th. Leerink Partners began coverage on Elanco Animal Health in a report on Monday, December 2nd. They set a "market perform" rating and a $14.00 price objective for the company. Finally, Morgan Stanley dropped their price target on Elanco Animal Health from $14.00 to $13.00 and set an "equal weight" rating on the stock in a research report on Wednesday, February 26th. Four analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $15.17.

Insider Transactions at Elanco Animal Health

In other news, Director Lawrence Erik Kurzius bought 10,000 shares of the stock in a transaction dated Tuesday, March 11th. The stock was bought at an average price of $10.20 per share, for a total transaction of $102,000.00. Following the purchase, the director now directly owns 111,459 shares in the company, valued at $1,136,881.80. This trade represents a 9.86 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.57% of the company's stock.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.